BRAF and melanoma: Moreover, these data, along with those of other groups, suggest that combination therapy with isoform-specific inhibitors of PI3K, tailored to the patient’s profile, may offer a means to prolong the duration of the response to MAPK-targeted therapies in patients with BRAF-mutant melanoma.